Insilico Medicine (03696) surged over 7%, reaching a high of HKD 61.3 to set another record high. As of the time of writing, the stock was up 2.02%, trading at HKD 58.15, with a turnover of HKD 48.2902 million. On the news front, Insilico Medicine recently entered into a multi-year R&D collaboration with Servier to utilize its AI platform, Pharma.AI, for the development of anti-tumor drugs. China Post Securities released a research report stating that Insilico Medicine possesses extensive experience in AI-driven oncology drug research and development, having established a pipeline covering multiple cancer indications. Among these, the pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412 have initiated global multi-center Phase I clinical trials, with an additional four oncology projects already out-licensed. Guotou Securities International indicated that Insilico Medicine boasts an impressive lineup of cornerstone investors and holds an industry-leading position in the field of AI drug discovery. The company's self-developed generative artificial intelligence platform, Pharma.AI, has already incubated over 20 assets in the clinical or IND application stage. Among these, three assets have been licensed to international pharmaceutical companies, with total contract values reaching up to $2.1 billion, and one Phase II asset is in the self-development stage.
Comments